Monday, December 30, 2019

AstraZeneca, Merck score win with Lynparza approval for pancreatic cancer

AstraZeneca, Merck score win with Lynparza approval for pancreatic cancer The drug is now the only approved medicine in biomarker-selected patients with advanced pancreatic cancer.

from Moneycontrol Business News https://ift.tt/35awRrv

No comments:

Post a Comment

Small and midcap stocks may face volatility, but long-term returns still strong: Vikas Khemani

​Every day there was some negative news flow, global concern, geopolitical concern, inflation concern, oil prices, commodity, everything was...